

EU Quality Management System Certificate

We hereby certify the company

PRIMA Lab SA
Viale Serfontana 10
6834 Morbio Inferiore
Switzerland

the introduction and application of a quality management system in accordance with Annex IX, Chapter I and III of Regulation (EU) 2017/746 for conformity assessment.

An audit by mdc has proven that this quality management system meets the following requirements:

Annex IX – Chapter I (Quality Management System)

of Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices.

Surveillance is carried out in accordance with Annex IX, Section 3 of Regulation (EU) 2017/746.

This certificate from mdc medical device certification GmbH (Notified Body 0483) consists of 2 pages. Details of the devices covered as well as further information and conditions are contained on the following pages.

Valid from 2026-04-29
Valid until 2028-10-25

Registration No. D1408400107
Report No. P26-00347-358547

Stuttgart, 2026-04-29



Notified Body

EU Authorized Representative:

QbD RepS BV
Groenenborgerlaan 16
2610 Wilrijk
Belgium
BE-AR-000000040

Devices:

Immunoassays for the detection of the presence of, or exposure to, a transmissible agent that causes a life-threatening disease with a high or suspected high risk of propagation

Risk class: D self-testing

Immunoassays intended to be used for screening / confirmation / of specific disorders / impairment

Risk class: C self-testing
W0102 IMMUNOCHEMISTRY (IMMUNOLOGY)
IVP 3007 In vitro diagnostic devices which require knowledge regarding immunoassays

Immunoassays intended to be used for detection of pregnancy or fertility testing

Risk class: B self-testing
IVR 0607 Devices intended to be used for detection of pregnancy or fertility testing

Notes:

For class A devices placed on the market in sterile condition the involvement of mdc is limited to the assessment of the aspects of manufacture concerned with securing and maintaining sterile conditions.

For devices for self-testing and near-patient testing the involvement of mdc additionally refers to the assessment of aspects according to Annex IX, Section 5.1.

For the placing on the market of class D devices an EU technical documentation assessment certificate is also required.

The certificate is based on the previous certificate

D1408400089 (2024-09-24)
D1408400102 (2025-09-11)

with the following changes to D1408400102:
Address change in certificate with remaining validity
Extension of scope to cover Class D (Self-Test)